Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
9.02
-0.40 (-4.25%)
At close: Oct 10, 2025, 4:00 PM EDT
8.90
-0.12 (-1.33%)
After-hours: Oct 10, 2025, 4:55 PM EDT
Anika Therapeutics Revenue
Anika Therapeutics had revenue of $28.22M in the quarter ending June 30, 2025, a decrease of -8.15%. This brings the company's revenue in the last twelve months to $91.85M, down -6.57% year-over-year. In the year 2024, Anika Therapeutics had annual revenue of $119.91M, down -0.73%.
Revenue (ttm)
$91.85M
Revenue Growth
-6.57%
P/S Ratio
1.14
Revenue / Employee
$397,736
Employees
288
Market Cap
130.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 119.91M | -885.00K | -0.73% |
Dec 31, 2023 | 120.79M | 6.97M | 6.12% |
Dec 31, 2022 | 113.83M | -33.97M | -22.98% |
Dec 31, 2021 | 147.79M | 17.34M | 13.29% |
Dec 31, 2020 | 130.46M | 15.85M | 13.83% |
Dec 31, 2019 | 114.61M | 9.06M | 8.58% |
Dec 31, 2018 | 105.56M | -7.87M | -6.93% |
Dec 31, 2017 | 113.42M | 10.04M | 9.71% |
Dec 31, 2016 | 103.38M | 10.38M | 11.16% |
Dec 31, 2015 | 93.00M | -12.60M | -11.93% |
Dec 31, 2014 | 105.60M | 30.51M | 40.64% |
Dec 31, 2013 | 75.08M | 3.72M | 5.22% |
Dec 31, 2012 | 71.36M | 6.58M | 10.16% |
Dec 31, 2011 | 64.78M | 9.22M | 16.60% |
Dec 31, 2010 | 55.56M | 15.42M | 38.42% |
Dec 31, 2009 | 40.14M | 4.36M | 12.17% |
Dec 31, 2008 | 35.78M | 4.95M | 16.06% |
Dec 31, 2007 | 30.83M | 3.99M | 14.86% |
Dec 31, 2006 | 26.84M | -2.99M | -10.04% |
Dec 31, 2005 | 29.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ANIK News
- 3 days ago - ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders - GlobeNewsWire
- 5 weeks ago - Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Anika Therapeutics: Undervalued HA Platform With 2027 Catalysts - Seeking Alpha
- 2 months ago - Anika Therapeutics, Inc. (ANIK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Anika Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update - GlobeNewsWire
- 3 months ago - Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025 - GlobeNewsWire
- 5 months ago - Anika Therapeutics, Inc. (ANIK) Q1 2025 Earnings Call Transcript - Seeking Alpha